Alpha 2.0
Login Register
» Articles » PMID: 20943724

Industry Sponsored Bias in Cost Effectiveness Analyses

Overview
Journal BMJ
Specialty General Medicine
Date 2010 Oct 15
PMID 20943724
Citations 8
Authors
Ava John-Baptiste
Chaim Bell
Affiliations
Soon will be listed here.
Citing Articles

Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020.

Haslam A, Lythgoe M, Akman E, Prasad V JAMA Netw Open. 2021; 4(11):e2135123.

PMID: 34792592 PMC: 8603079. DOI: 10.1001/jamanetworkopen.2021.35123.

Economic Evaluations in National Cancer Institute-Sponsored Network Cancer Clinical Trials.

Nghiem V, Vaidya R, Lyman G, Hershman D, Ramsey S, Unger J Value Health. 2020; 23(12):1653-1661.

PMID: 33248521 PMC: 8262264. DOI: 10.1016/j.jval.2020.08.2095.

Prevention of Surgical Site Infections: A Systematic Review of Cost Analyses in the Use of Prophylactic Antibiotics.

Purba A, Setiawan D, Bathoorn E, Postma M, Dik J, Friedrich A Front Pharmacol. 2018; 9:776.

PMID: 30072898 PMC: 6060435. DOI: 10.3389/fphar.2018.00776.

A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?.

St Peter W, Wazny L, Weinhandl E, Cardone K, Hudson J Drugs. 2017; 77(11):1155-1186.

PMID: 28584909 DOI: 10.1007/s40265-017-0758-5.

Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go.

Rizk R BMC Nephrol. 2016; 17(1):75.

PMID: 27393192 PMC: 4938934. DOI: 10.1186/s12882-016-0286-7.